The goal of this translational research project is to generate preclinical data and demonstrate regenerative engineered tissue as a superior tissue replacement over fixed pericardium for a pulmonary valve replacement in young patients.
This research tests a new product for patients who have had a heart attack (AMI, acute myeocardial infarction). This product would help protect and regenerate cells in a heart damaged by AMI.
Rion is a clinical‐phase regenerative medicine company based in Rochester, MN, focused on bringing novel regenerative technologies solving unmet medical needs of the people of Minnesota.
Cardiovascular disease is the most common cause of death in the United States, and many patients need heart transplants to survive. Currently, heart transplantation is limited based on the scarcity of donor organs. This proposal aims to see if it is possible to develop humanized and personalized hearts in gene-edited animals.